Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.

Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, Simpson SH.

Diabetes Obes Metab. 2015 Jun;17(6):523-32. doi: 10.1111/dom.12456. Epub 2015 Mar 20. Review.

PMID:
25711240
2.

[Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].

Asvold BO, Jonsbu M, Grill V.

Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2560-4. Review. Norwegian.

PMID:
11070997
3.

Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Huupponen R.

Med Toxicol. 1987 May-Jun;2(3):190-209. Review.

PMID:
3298923
4.

Comparative tolerability of sulphonylureas in diabetes mellitus.

Harrower AD.

Drug Saf. 2000 Apr;22(4):313-20. Review.

PMID:
10789825
5.

[Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial].

Gallwitz B, Thiemann S, Wörle HJ, Marx N.

Dtsch Med Wochenschr. 2015 May;140(11):831-4. doi: 10.1055/s-0041-102194. Epub 2015 May 28. Review. German.

PMID:
26080724
6.

The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes.

Kar P, Holt RI.

Cardiovasc Drugs Ther. 2008 Jun;22(3):207-13. doi: 10.1007/s10557-008-6090-2. Epub 2008 Feb 21. Review.

PMID:
18288596
7.

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ.

Diab Vasc Dis Res. 2013 Jul;10(4):289-301. doi: 10.1177/1479164112475102. Epub 2013 Feb 28. Review.

PMID:
23449634
8.

Mortality risk with sulphonylureas compared to metformin.

Holden SE, Currie CJ.

Diabetes Obes Metab. 2014 Oct;16(10):885-90. doi: 10.1111/dom.12280. Epub 2014 Mar 14.

PMID:
24533964
9.

Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs.

Johnsen SP, Monster TB, Olsen ML, Thisted H, McLaughlin JK, Sørensen HT, Lervang HH, Rungby J.

Am J Ther. 2006 Mar-Apr;13(2):134-40.

PMID:
16645430
10.

[Effect of antidiabetic treatment in ischemic heart diseases].

Pogätsa G, Simon J, Koltai MZ, Ballagi-Pordány G, Aranyi Z.

Orv Hetil. 1990 Jan 21;131(3):119-26. Review. Hungarian.

PMID:
2405334
11.

Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality.

Shimoda M, Kaku K.

J Diabetes Investig. 2016 Sep;7(5):674-6. doi: 10.1111/jdi.12494. Epub 2016 Mar 24.

12.

Sulphonylureas and cardiovascular disease: a problem for few diabetics.

Slater SD, Ireland JT.

Scott Med J. 1979 Jan;24(1):17-20.

PMID:
493926
13.
14.

The role of hypoglycemic sulphonylureas in arrhythmias contributing to the mortality in acute myocardial ischemia.

Koltai MZ, Aranyi Z, Ballagi-Podány G, Pogátsa G.

Acta Physiol Hung. 1990;75 Suppl:175-6. No abstract available.

PMID:
2371854
15.

Are hypoglycaemia and other adverse effects similar among sulphonylureas?

Salas M, Caro JJ.

Adverse Drug React Toxicol Rev. 2002;21(4):205-17. Review.

PMID:
12503254
16.

Sulphonylureas--action and uses.

Ferrier TM.

Aust Fam Physician. 1976 Jul;5(6):865-6.

PMID:
999566
17.

[Clinically important effects of oral antidiabetic drug interactions].

Drzewoski J, Kopff B.

Pol Merkur Lekarski. 2000 Sep;9(51):605-7. Review. Polish.

PMID:
11126985
18.

Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas.

Gallwitz B, Häring HU.

Diabetes Obes Metab. 2010 Jan;12(1):1-11. doi: 10.1111/j.1463-1326.2009.01095.x. Epub 2009 Sep 24. Review.

PMID:
19788431
19.
20.

Oral hypoglycemic drugs and cardiovascular pathology.

Mincu I, Cheţa D.

Med Interne. 1979 Apr-Jun;17(2):111-23. Review.

PMID:
382336

Supplemental Content

Support Center